1-(2,5-difluorobenzyl)-7-[4-((S)-2-[(pyrrolidin-1-yl)methyl]pyrrolidine-1-carbonyl)phenyl]-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one | 957194-30-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-(2,5-difluorobenzyl)-7-[4-((S)-2-[(pyrrolidin-1-yl)methyl]pyrrolidine-1-carbonyl)phenyl]-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one
• 英文别名: (S)-1-(2,5-difluorobenzyl)-7-(4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)phenyl)-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-one；1-[(2,5-difluorophenyl)methyl]-7-[4-[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]phenyl]-3,4-dihydropyrido[2,3-b]pyrazin-2-one
• CAS: 957194-30-8
• 化学式: C₃₀H₃₁F₂N₅O₂
• 分子量: 531.605
• InChiKey: JTZMBBMMIOHIOW-VWLOTQADSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  68.8
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-[1-(2,5-difluorobenzyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-7-yl]benzoic acid 、 (S)-(pyrrolidinemethyl)pyrrolidine 以to give the title compound as a white solid (32% yield)的产率得到1-(2,5-difluorobenzyl)-7-[4-((S)-2-[(pyrrolidin-1-yl)methyl]pyrrolidine-1-carbonyl)phenyl]-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one
  参考文献：
  名称：

  Pyridopyrazines and derivatives thereof as ALK and c-MET inhibitors

  摘要：

  本发明提供了公式I的化合物或其药学上可接受的盐形式，其中A，L1，R1，R2，R3，R4，R5，R6和X的定义如本文所述。公式I的化合物具有ALK和/或c-Met抑制活性，并可用于治疗ALK或c-Met介导的疾病或病况。

  公开号：

  US07919502B2

文献信息

• Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors
  申请人：Dorsey D. Bruce

  公开号：US20080032972A1

  公开（公告）日：2008-02-07

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

  本发明提供了化合物I的结构或其药学上可接受的盐形式，其中A、L1、R1、R2、R3、R4、R5、R6和X的定义如本文所述。化合物I具有ALK和/或c-Met抑制活性，并可用于治疗ALK或c-Met介导的疾病或病症。
• Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
  申请人：Cephalon, Inc.

  公开号：US08080561B2

  公开（公告）日：2011-12-20

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

  本发明提供了公式I的化合物或其药学上可接受的盐形式，其中A，L1，R1，R2，R3，R4，R5，R6和X的定义如本文所述。公式I的化合物具有ALK和/或c-Met抑制活性，并可用于治疗ALK或c-Met介导的疾病或病况。
• Pyridopyrazines and derivatives thereof as ALK and c-MET inhibitors
  申请人：Cephalon, Inc.

  公开号：US07919502B2

  公开（公告）日：2011-04-05

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt form thereof, wherein A, L1, R1, R2, R3, R4, R5, R6, and X are as defined herein. The compounds of Formula I have ALK and/or c-Met inhibitory activity, and may be used to treat ALK- or c-Met-mediated disorders or conditions.

  本发明提供了公式I的化合物或其药学上可接受的盐形式，其中A，L1，R1，R2，R3，R4，R5，R6和X的定义如本文所述。公式I的化合物具有ALK和/或c-Met抑制活性，并可用于治疗ALK或c-Met介导的疾病或病况。
• Synthesis and structure–activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase
  作者：Karen L. Milkiewicz、Linda R. Weinberg、Mark S. Albom、Thelma S. Angeles、Mangeng Cheng、Arup K. Ghose、Renee C. Roemmele、Jay P. Theroff、Ted L. Underiner、Craig A. Zificsak

  DOI：10.1016/j.bmc.2010.04.087

  日期：2010.6.15

  Dysregulation of the anaplastic lymphoma kinase (ALK) is implicated in a variety of cancers. A series of tetrahydropyrido[2,3-b]pyrazines was constructed as ring-constrained analogs of a known aminopyridine kinase scaffold. Chemistry was developed to rapidly elaborate the SAR, structural elements impacting ALK inhibitory activity were exploited, and kinase selective analogs were identified that inhibit ALK with IC50 values similar to 10 nM (enzyme) and similar to 150 nM (cell). (C) 2010 Elsevier Ltd. All rights reserved.
• PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS
  申请人：CEPHALON, INC.

  公开号：EP2091951B1

  公开（公告）日：2018-02-28